



## San Antonio bioscience companies to team up on critical research

Two San Antonio-based bioscience companies — [StemBioSys](#) Inc. and Cardioate Inc. — have agreed to work in tandem on new stem cell research that could have significant implications on regenerative medicine.

The two companies will seek to identify potential benefits from combining Cardioate's proprietary NeoVessel graft technology with StemBioSys' High Performance Microenvironment (HPME) technology. The collaborative project is expected to last four to six months, and officials with the two entities believe combining their respective technologies may further enhance the performance of the NeoVessel vascular graft material.

StemBioSys President and CEO Bob Hutchens said this project provides an opportunity to “partner with a peer biotech company right here in San Antonio” on joint research that could benefit both organizations' respective research efforts. He expects that collaborating with Cardioate will further enhance the value of StemBioSys' HPME platform and open up a broad range of of clinical and therapeutic applications for the companies' technologies.

Cardioate's NeoVessel technology has already shown positive results in animal studies, according to Hutchens, who said the decision by both companies to collaborate could further validate StemBioSys' HPME platform and lead to better clinical outcomes.

Cardioate President and CEO Mark Standeford said his company will have an opportunity to increase the performance of its NeoVessel technology and significantly enhance its value in target market applications by utilizing the HPME platform.

If the project proves successful, StemBioSys and Cardioate could pursue an expanded collaborative agreement.

Standeford said Cardioate and StemBioSys will explore “how these two companies can work together in other applications.”

Source: <http://www.bizjournals.com/sanantonio/news/2015/05/11/san-antonio-bioscience-companies-to-team-up-on.html>

May 11th 2015